Back to top
more

Avenue Therapeutics (ATXI)

(Delayed Data from NSDQ)

$2.72 USD

2.72
133,730

-0.15 (-5.23%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $2.62 -0.10 (-3.68%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Nitish Marwah headshot

4 Affordable Breakout Stocks for Stunning Returns

Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.

Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session

Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Avenue Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Avenue Therapeutics

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Flexion (FLXN) Soars: Stock Adds 6.6% in Session

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?

Is (ATXI) Outperforming Other Medical Stocks This Year?

Kinjel Shah headshot

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.

Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide

Zacks.com featured highlights include: Veritone, Avenue Therapeutics, Turtle Beach, BJ???s Wholesale Club and Atlas Air Worldwide

Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings

Zacks.com featured highlights include: Avenue Therapeutics, Glu Mobile, Yamana Gold and Z Holdings

How Avenue (ATXI) Stock Stands Out in a Strong Industry

Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Nilanjan Choudhury headshot

Pick These 5 Stocks With Superb Relative Price Strength

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Nitish Marwah headshot

4 Breakout Stocks for Impressive Returns

The logic behind the breakout strategy for stock selection is to identify stocks are trading within a narrow band.

Sanghamitra Saha headshot

Technology on Solid Footing: 5 Stocks With More Room to Run

Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.

Zoetis' (ZTS) Q1 Earnings Beat Estimates, Revenues In Line

Zoetis (ZTS) beats on earnings in the first quarter of 2020 while sales meet estimates. Domestic revenues bumped up owing to growth in new parasiticide products and a robust dermatology portfolio.

Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?

During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.

Top Ranked Momentum Stocks to Buy for April 27th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia

Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick

Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Nalak Das headshot

5 Top Small-Cap Stocks Braving Coronavirus Bloodbath

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).